Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal vs hydrochloride bupivacaine for femoral nerve block after ACL reconstruction
ChiCTR2600124270Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- May 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative pain comparing Experimental group: bupivacaine + liposomal bupivacaine with Control group: bupivacaine monotherapy (2 arms). Primary endpoint: Area under NRS score curve (AUC) at rest 12–72 hours postoperatively. Planned start May 2026; status: not yet recruiting.
02
Drugs
bupivacaineliposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600124270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124270.